IceCure Medical Establishes New $4.34M At-The-Market Offering Program

summarizeSummary

IceCure Medical has launched a new At-The-Market offering program to sell up to $4.34 million in ordinary shares, a move that is highly dilutive and aims to bolster working capital amidst financial concerns.

check_boxKey Events

• New At-The-Market (ATM) Offering Program

  IceCure Medical Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners to offer and sell up to $4,339,697 of its ordinary shares from time to time through an At-The-Market offering.

• Significant Potential Dilution

  The maximum offering amount of $4.34 million represents approximately 26.32% of the company's current market capitalization, indicating a highly dilutive capital raise.

• Purpose of Funds

  Net proceeds from the sale of shares are intended for working capital and general corporate purposes.

• Context of Financial Need

  This new ATM program follows a previous $100 million shelf registration filed on March 20, 2026, and a $4.0 million registered direct offering on March 27, 2026, all against the backdrop of a 'going concern' warning disclosed on March 17, 2026.

auto_awesomeAnalysis

IceCure Medical has entered into a new At-The-Market (ATM) sales agreement to potentially raise up to $4.34 million. This capital raise is highly dilutive, representing over 26% of the company's current market capitalization. The proceeds are earmarked for working capital and general corporate purposes, indicating an ongoing need for funds, especially in light of the company's previously disclosed 'going concern' warning.